Avalon GloboCare issues update on its partnership with the Institute for Synthetic Bioarchitectures in Vienna, Austria

Avalon GloboCare Corp. (NASDAQ:AVCO) has issued an update on its partnership with the Institute for Synthetic Bioarchitectures at the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria. The collaboration brings together BOKU’s S-layer nanotechnology with Avalon’s expertise in biomanufacturing, cell therapy engineering, and clinical development. Avalon plans to leverage the pioneering work of Professor Uwe B. Sleytr, a world-renowned scientist and pioneer in nanobiotechnology, who is among the foremost experts on basic and applied surface layer (S-layer) technology, and Professor Emeritus in the Department of Nanobiotechnology at BOKU. Professor Sleytr is also a member of Avalon’s Scientific and Clinical Advisory Board. READ: Avalon Globocare featured in article running in Nature’s Biopharma Dealmaker December edition Applied S-layer nanotechnology enables the creation of uniform matrices of certain proteins or molecules and is based on the repetitive protein structures that make up the outer surface of microbial cells. Adding a coat of an S-layer onto solid surfaces can greatly improve the function of a therapeutic, vaccine, or device. The S-layer allows enhanced efficiency and interaction of targeted proteins and molecules for better function. Avalon is currently utilizing S-layer technology to develop an intranasal, spray vaccine candidate against SARS-CoV-2, the virus that causes coronavirus (COVID-19), and also for the development of additional vaccines, targeted drug delivery, diagnostic devices and other therapeutic applications. Avalon and BOKU are establishing a state-of-the-art research facility, the Christian Doppler Laboratory, located on the BOKU campus in Vienna, Austria, under the scientific leadership of Professor Eva-Kathrin Ehmoser, the Head of BOKU’s Institute for Synthetic Bioarchitectures and Professor Sleytr, a member of the Austrian Academy of Sciences. In connection with the new facility, Avalon and BOKU have signed a Memorandum of Understanding (MOU) to jointly apply for a matching research grant from the prestigious Christian Doppler Laboratory Foundation. In the December 2020 issue of Nature’s Biopharma Dealmakers, Avalon’s president and CEO, Dr David Jin, highlighted Avalon’s ongoing scientific and clinical developments including a first-in-human trial of a mucosal, intranasal vaccine against SARS-CoV-2 that is planned for early 2021. Dr Jin also described the company’s innovative, allogeneic mesenchymal stromal cell (MSC) therapy candidate, CB-MSC-1, which possess unique anti-inflammatory and immunomodulatory activities, as well as AVA-001, Avalon’s third-generation CAR T cell therapy that has shown robust activity in patients with relapsed, refractory B cell acute lymphoblastic leukemia in a Phase 1 trial. “We are thrilled to fast-track our scientific and clinical research together with Avalon, as well as leverage Avalon’s clinical expertise and networks to translate these advancements into clinical programs,” said Professor Ehmoser in a statement. “We look forward to continuing this fruitful partnership.” “We are excited and motivated to join forces with the researchers at BOKU to drive innovation. We have already begun a collaboration on the mucosal SARS-CoV-2 vaccine and are moving quickly to establish additional joint research endeavors to bring about innovative technologies and new medicines to patients,” added Dr Jin. Avalon GloboCare is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX), and regenerative therapeutics.  Contact the author at jon.hopkins@proactiveinvestors.com